IL136551A0 - Preparation of peg-grf conjugates - Google Patents

Preparation of peg-grf conjugates

Info

Publication number
IL136551A0
IL136551A0 IL13655198A IL13655198A IL136551A0 IL 136551 A0 IL136551 A0 IL 136551A0 IL 13655198 A IL13655198 A IL 13655198A IL 13655198 A IL13655198 A IL 13655198A IL 136551 A0 IL136551 A0 IL 136551A0
Authority
IL
Israel
Prior art keywords
grf
conjugates
peg
preparation
grf conjugates
Prior art date
Application number
IL13655198A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of IL136551A0 publication Critical patent/IL136551A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL13655198A 1997-12-03 1998-12-01 Preparation of peg-grf conjugates IL136551A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97121264A EP0922446A1 (en) 1997-12-03 1997-12-03 Solution-phase site-specific preparation of GRF-PEG conjugates
PCT/EP1998/007748 WO1999027897A1 (en) 1997-12-03 1998-12-01 Site-specific preparation of polyethylene glycol-grf conjugates

Publications (1)

Publication Number Publication Date
IL136551A0 true IL136551A0 (en) 2001-06-14

Family

ID=8227732

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13655198A IL136551A0 (en) 1997-12-03 1998-12-01 Preparation of peg-grf conjugates
IL136551A IL136551A (en) 1997-12-03 2000-06-04 Preparation of PEG-GRF-linked

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL136551A IL136551A (en) 1997-12-03 2000-06-04 Preparation of PEG-GRF-linked

Country Status (30)

Country Link
US (3) US6528485B1 (ru)
EP (2) EP0922446A1 (ru)
JP (2) JP2001524505A (ru)
KR (1) KR100561768B1 (ru)
CN (1) CN1149967C (ru)
AR (1) AR017780A1 (ru)
AT (1) ATE236607T1 (ru)
AU (1) AU755285B2 (ru)
BG (1) BG64815B1 (ru)
BR (1) BR9815159A (ru)
CA (1) CA2312004C (ru)
DE (1) DE69813291T2 (ru)
DK (1) DK1037587T3 (ru)
EA (1) EA004269B1 (ru)
EE (1) EE200000319A (ru)
ES (1) ES2194376T3 (ru)
HK (1) HK1034203A1 (ru)
HU (1) HUP0100507A3 (ru)
IL (2) IL136551A0 (ru)
NO (1) NO327238B1 (ru)
NZ (1) NZ504570A (ru)
PL (1) PL192082B1 (ru)
PT (1) PT1037587E (ru)
SI (1) SI1037587T1 (ru)
SK (1) SK8242000A3 (ru)
TR (1) TR200001615T2 (ru)
TW (1) TWI254641B (ru)
UA (1) UA73716C2 (ru)
WO (1) WO1999027897A1 (ru)
ZA (1) ZA9811068B (ru)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
AU2001295589B2 (en) * 2000-10-05 2005-10-13 Ares Trading S.A. Regioselective liquid phase pegylation
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
EP1465933B1 (en) * 2002-01-16 2007-08-29 Biocompatibles UK Limited Polymer conjugates
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
CN1688696A (zh) * 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 Ghrh类似物
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
WO2004065412A1 (en) * 2003-01-18 2004-08-05 Pegsphere Co., Ltd. Peptides having protected amines of untargeted sites, methods for production thereof and of specifically conjugated peg peptides using the same
US20050058658A1 (en) * 2003-07-15 2005-03-17 Barros Research Institute Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
EP1644408A1 (en) * 2003-07-15 2006-04-12 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
AU2004311630A1 (en) * 2003-12-02 2005-07-21 Cytimmune Sciences, Inc. Methods and compositions for the production of monoclonal antibodies
CA2554755A1 (en) * 2004-01-28 2005-08-11 Cytimmune Sciences, Inc. Functionalized colloidal metal compositions and methods
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α-干扰素1b的制备方法
US20050261475A1 (en) * 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
EP2371856B1 (en) 2004-11-12 2022-05-18 Bayer HealthCare LLC Site-directed modification of FVIII
BRPI0614185B1 (pt) * 2005-07-26 2015-10-27 Rhodia polímero com grupos substituintes poli (alquileneoxi) pendentes, composição de cuidados pessoais e método para cuidar do cabelo ou da pele
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
JP5313129B2 (ja) 2006-05-02 2013-10-09 アロザイン, インコーポレイテッド 非天然アミノ酸置換ポリペプチド
EP2054074B8 (en) * 2006-08-04 2014-11-12 Prolong Pharmaceuticals, LLC Modified erythropoietin
US20080083154A1 (en) * 2006-10-05 2008-04-10 Timothy M Gregory Bait retention fish hook
CA2707840A1 (en) 2007-08-20 2009-02-26 Allozyne, Inc. Amino acid substituted molecules
EP2200932A4 (en) * 2007-09-21 2014-09-10 Cytimmune Sciences Inc NANOTHERAPEUTIC COLLOIDAL METAL COMPOSITIONS AND METHODS
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
CA2742710A1 (en) * 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
ES2587397T3 (es) * 2009-03-20 2016-10-24 Hanmi Science Co., Ltd. Procedimiento para preparar un conjugado específico de sitio de un polipéptido fisiológicamente activo
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
US20100267635A1 (en) * 2009-04-20 2010-10-21 Theratechonolgies Inc. Use of protease inhibitors and grf molecules in combination therapy
EP2445536B1 (en) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Methods and compositions using peptides and proteins with c-terminal elements
US20110105397A1 (en) 2009-11-04 2011-05-05 Gengo Peter J Method for treating heart failure with stresscopin-like peptides
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
CN103547591A (zh) 2011-04-21 2014-01-29 瑟瑞技术公司 生长激素释放因子(grf)类似物及其用途
WO2012166585A2 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
WO2016187712A1 (en) 2015-05-28 2016-12-01 Institut National De La Recherche Scientifique Inhibitors of prototypic galectin dimerization and uses thereof
PT3445778T (pt) * 2016-04-19 2020-10-15 Griffon Pharmaceuticals Int Sa C/O Biopole Sa Péptidos bioativos peguilados e suas utilizações
CN110317826B (zh) * 2019-05-22 2020-11-10 中国农业大学 调控PvGRF9含量或活性的物质在调控植物茎生长发育中的应用
WO2021133407A1 (en) 2019-12-27 2021-07-01 Compagnie Generale Des Etablissements Michelin Rubber mix with high specific surface area and high structure acetylene carbon black
AR124707A1 (es) 2021-01-28 2023-04-26 Talem Therapeutics Llc Anticuerpos antiglicoproteína de espiga y su uso terapéutico
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
ES2085297T3 (es) * 1989-05-27 1996-06-01 Sumitomo Pharma Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
AU656144B2 (en) * 1990-06-29 1995-01-27 F. Hoffmann-La Roche Ag Histidine substituted growth hormone releasing factor analogs
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
WO1992018531A1 (en) * 1991-04-09 1992-10-29 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
EP0518295A3 (en) * 1991-06-14 1993-09-01 Millipore Corporation Allyl side chain protection in peptide synthesis
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1997017367A1 (en) * 1995-11-03 1997-05-15 Theratechnologies Inc. Method of grf peptides synthesis

Also Published As

Publication number Publication date
CA2312004C (en) 2009-05-19
DK1037587T3 (da) 2003-07-28
NO20002664D0 (no) 2000-05-24
PL341139A1 (en) 2001-03-26
PL192082B1 (pl) 2006-08-31
US6869932B2 (en) 2005-03-22
EP1037587B1 (en) 2003-04-09
US7317002B2 (en) 2008-01-08
HK1034203A1 (en) 2001-10-19
KR20010032494A (ko) 2001-04-25
EE200000319A (et) 2001-08-15
SK8242000A3 (en) 2001-01-18
SI1037587T1 (en) 2003-08-31
DE69813291T2 (de) 2003-11-13
CA2312004A1 (en) 1999-06-10
TWI254641B (en) 2006-05-11
AU755285B2 (en) 2002-12-05
WO1999027897A9 (en) 1999-09-30
TR200001615T2 (tr) 2000-12-21
US20050159353A1 (en) 2005-07-21
JP2001524505A (ja) 2001-12-04
BG104484A (en) 2000-12-29
CN1149967C (zh) 2004-05-19
ZA9811068B (en) 1999-06-28
KR100561768B1 (ko) 2006-03-16
HUP0100507A3 (en) 2001-11-28
IL136551A (en) 2008-12-29
CN1280483A (zh) 2001-01-17
NZ504570A (en) 2003-10-31
BG64815B1 (bg) 2006-05-31
PT1037587E (pt) 2003-08-29
US6528485B1 (en) 2003-03-04
BR9815159A (pt) 2000-10-10
UA73716C2 (en) 2005-09-15
JP2010024245A (ja) 2010-02-04
AU1563399A (en) 1999-06-16
DE69813291D1 (de) 2003-05-15
ES2194376T3 (es) 2003-11-16
ATE236607T1 (de) 2003-04-15
EA004269B1 (ru) 2004-02-26
NO20002664L (no) 2000-07-13
EP1037587A1 (en) 2000-09-27
EA200000601A1 (ru) 2000-12-25
HUP0100507A2 (hu) 2001-08-28
EP0922446A1 (en) 1999-06-16
NO327238B1 (no) 2009-05-18
US20040029794A1 (en) 2004-02-12
JP5431874B2 (ja) 2014-03-05
WO1999027897A1 (en) 1999-06-10
AR017780A1 (es) 2001-10-24

Similar Documents

Publication Publication Date Title
IL136551A0 (en) Preparation of peg-grf conjugates
GB9713980D0 (en) New conjugates
EP1020193A4 (en) ORAL PREPARATION
GB9713703D0 (en) Preparation of opiates
PL339551A1 (en) Derivatives of rezorcin
GB9715751D0 (en) Formulations
EP1017379A4 (en) THERAPEUTIC COMPOSITIONS
EP1033994A4 (en) METHOD FOR PRODUCING BIOGINKGO
PL335700A1 (en) Novel preparation
PL337970A1 (en) Novel preparation
EP0976381A4 (en) PREPARATION FOR DERMATOLOGICAL USE
ZA982073B (en) Pharmaceutical preparation
CY2590B2 (en) Preparation of 1-butyl-4-piperidinylmethylamine
PL334769A1 (en) Derivatives of 5-aroylnaphtene
HUP9902855A3 (en) Preparation of sterol- and stanol-esters
AU8102498A (en) Preparation of diaryl-benzopyrans
PL338777A1 (en) Derivative of piperidinylmethyloxazolydinone
ZA985064B (en) Derivatives of pentaerythrits
IL124387A0 (en) Preparation of 5-Methyleneoxazolines
GB2329384B (en) Preparation of 1-chloro-1-cyclopropylethene
PL325816A1 (en) Novel derivatives of naphtylpiperazine
GB2322372B (en) Preparation of 2-Mercaptothiazole
GB9702652D0 (en) Conjugates and their preparation
TW312301U (en) Improved structure of earmask
TW319017U (en) Improved structure of mousetraps